Astrazeneca Pharma India Ltd vs Wanbury Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Wanbury Ltd changed from 3.4 on March 2022 to 25.2 on March 2025 . This represents a CAGR of 65.00% over 4 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Wanbury Ltd changed from ₹ 207.5 crore on March 2021 to ₹ 768.96 crore on March 2025 . This represents a CAGR of 29.95% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Wanbury Ltd for the Jun '25 is ₹ 163.53 crore as compare to the Mar '25 revenue of ₹ 173.84 crore. This represent the decline of -5.93% The ebitda of Astrazeneca Pharma India Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Wanbury Ltd for the Jun '25 is ₹ 24.79 crore as compare to the Mar '25 ebitda of ₹ 31.47 crore. This represent the decline of -21.23% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 5 quarters. This represents a CAGR of 0.0% The net profit of Wanbury Ltd changed from ₹ 1.04 crore to ₹ 13.49 crore over 5 quarters. This represents a CAGR of 676.93% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Wanbury Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Wanbury Ltd

Wanbury Limited, formerly known Pearl Organics Limited was incorporated in August, 1988.
The Company attained its present name in September 2004.
The Company is engaged in the business of pharmaceutical and related activities, including research. The company has established its first plant in the year 1992 in Tarapur for manufacturing APIs.
In 1995, the Company acquired plant of Brij Chemicals Pvt Ltd at Patalganga.
In 1996, it entered into a strategic alliance with Wyckoff Chemicals to manufacture its API in US. In 2007-08, the merger of Doctors Organic Chemicals Limited (DOCL) with the Company became effective from 1st April, 2007.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Wanbury Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Wanbury Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,543 Cr while Market cap of Wanbury Ltd is 901 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Wanbury Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Wanbury Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Wanbury Ltd?

As of May 4, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8217.2. On the other hand, Wanbury Ltd stock price is INR ₹257.9.

How do dividend payouts of Astrazeneca Pharma India Ltd and Wanbury Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Wanbury Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.